RU58841 combined with finasteride or dutasteride is more effective than RU58841 alone for hair loss. Users suggest combining these with minoxidil and microneedling for better results.
A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.
The user experienced significant hair regrowth using 1mg oral finasteride daily and recently added minoxidil 5% to address remaining gaps. They reported no significant side effects, attributing any perceived changes to weight fluctuations rather than the medication.
The user experienced great results using topical finasteride and minoxidil twice daily for hair regrowth. They reported no side effects and found it easier to apply the treatment with shorter hair.
The user started using finasteride and minoxidil three months ago and reports new hair growth with no side effects. The regimen includes minoxidil foam 5% twice daily, finasteride 1.25 mg daily, and weekly microneedling.
A user's hair growth progress over 5 months using Fin 2.5mg gel and Redensyl serum, with the user noticing baby hairs and an improvement in thickness. Another user asked what redensyl serum was and the response was appreciation for noticing the hair loss early on.
A 23-year-old started using 0.5mg Dutasteride and 2.5mg Minoxidil daily for hair loss and is considering adding RU58841 or GHK-cu. Users suggest waiting a few months before adding anything and mention Koshine's kx-826 as a potentially better alternative to RU58841.
Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.
Minoxidil, finasteride, and RU58841 promote hair growth by different mechanisms, with minoxidil and prostaglandin E1 being specifically mentioned. Corticosteroids can also cause hair growth.
The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user is considering two hair loss treatments: Minoxidilmax Maxogen-x, which contains Minoxidil, Finasteride, Azelaic Acid, ABN Complex, Retinoic Acid, Fluocinolone, and Caffeine, and Morr-F, which contains only Minoxidil and Finasteride. They are asking for others' experiences with these brands.
A user increased their RU58841 treatment from 5% to 8% to combat hair loss and is questioning the effectiveness of the higher dosage. Another user shared their extensive hair loss treatment regimen, suggesting that while 8% RU58841 might not significantly change results, it's worth trying as individual responses vary.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.
The user has been using finasteride for seven months and oral minoxidil for two months, along with redensyl serum and GFC sessions, but is not seeing improvement in hair loss. They are feeling helpless and questioning if they are a non-responder to the treatments.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
People on testosterone replacement therapy (TRT) with aggressive androgenetic alopecia (AGA) discuss using Dutasteride or Finasteride, sometimes combined with topical treatments like RU58841 or CB-03-01 (Breezula), to prevent hair loss. Concerns about side effects and costs of certain treatments are mentioned, with one individual sharing their experience of slowed hair loss using Finasteride alone.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.
The conversation discusses the effectiveness of finasteride and microneedling for treating hair loss. The linked article is seen as an advertisement for these treatments.
The user has been using finasteride and minoxidil since September 2019 and has seen significant hair regrowth. Their routine includes a compounded topical with minoxidil, finasteride, dutasteride, and retinol at night, and 1mg finasteride in the morning.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The user regrets stopping finasteride and minoxidil due to side effects but plans to resume treatment. They consider using finasteride every other day and continuing topical minoxidil to manage side effects while maintaining hair.
The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
A user's experience with hair loss and their consideration of using finasteride, minoxidil, RU58841, stemoxydine, fluridil, and peptide serum with redensyl as treatment options.
Significant hair regrowth was achieved using 1mg finasteride and 5% topical minoxidil over 14 months, with only initial shedding and mild scalp irritation as side effects. Consistency and early treatment are recommended for optimal results.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.
OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.